N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid, Neisseria Meningitidis Group A Polysaccharide Conjugated To Tetanus Toxoid Carrier Protein, Neisseria Meningitidis Group W-135 Polysaccharide Conjugated To Tetanus Toxoid Carrier Protein, Neisseria Meningitidis Group Y Polysaccharide Conjugated To Tetanus Toxoid Carrier Protein

8 trials 1 recruiting JAnti-infectives

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

1 Recruiting

6 Completed trials

6 Sponsors

15 Countries

Phase III

Phase II

Phase I/II

Phase IV

Phase I (Other)

Phase III: 2 Phase II: 2 Phase I/II: 1 Phase IV: 2 Phase I (Other): 1

Oversight events:

2 temporary halts 1 unexpected event across 1 trial

View oversight register →

Indications tested

C3 glomerulopathy 1 Myasthenia gravis 1 Meningococcal infection 1 Meningococcal immunisation 1 Meningitis meningococcal 1

Sponsors using this IMP

Rijksinstituut voor Volksgezondheid en Milieu (RIVM) 2 Sanofi Pasteur 2 Apellis Pharmaceuticals Inc. 1 Dianthus Therapeutics Inc. 1 GlaxoSmithKline Biologicals 1 Moderna Inc. 1

All trials

8 total

EarLy extra Measles immunisation during a measles Outbreak (ELMO) Pending

2024-513395-18-00 Phase IV 1 country Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting

2024-512865-15-00 Phase II 9 countries Dianthus Therapeutics Inc.
Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers,… Ended

2023-510465-10-00 Phase II 6 countries Sanofi Pasteur Inc.
Men4age study Ended

2024-513640-29-00 Phase IV 1 country Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
A study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoprolifer… Ended

2023-504625-39-00 Phase III 8 countries Apellis Pharmaceuticals Inc.
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended

2022-502022-41-00 Phase I (Other) 3 countries Moderna Inc.
Study on immunogenicity and safety of a meningococcal ACYW conjugate vaccine in healthy infants and toddlers Ended

2023-508177-85-00 Phase III 6 countries Sanofi Pasteur
MENACWY=MEN7B-003 Ended

2023-506449-40-00 Phase I/II 3 countries GlaxoSmithKline Biologicals

Showing 1–8 of 8 trials

← All drugs A–Z